Source: Aurora Spine Corporation.
  • Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors
  • 11,220,930 units will be issued at a price of $0.58 per common share and associated common warrant
  • It expects the closing date to occur on or about September 17, 2021
  • Aurora Spine Corporation brings new solutions to the spinal implant market through minimally invasive regenerative spinal implant technologies
  • Aurora Spine Corporation (ASG) closed down by 10.94 per cent trading at $0.57 per share

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.

It will issue up to 11,220,930 units priced at $0.58 per common share and associated common warrant.

Each warrant entitles the holder to purchase one common share for $0.75 for up to three years after the closing of the offering.

Aurora expects the closing date to occur on or about September 17, 2021.

Aurora will offer shares and warrants in the United States on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933.

No securities will be sold or offered for sale in Canada.

Aurora Spine Corporation brings new solutions to the spinal implant market through minimally invasive regenerative spinal implant technologies.

Aurora Spine Corporation (ASG) closed down by 10.94 per cent trading at $0.57.

More From The Market Online

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.

FDA grants full approval to Pfizer’s colorectal cancer treatment

The FDA granted full approval to Pfizer’s (NYSE:PFE) BRAFTOVI + cetuximab + fluorouracil based chemotherapy for adults.